Obesity and metabolic syndrome in COPD: is exercise the answer?

Benjamin D James¹, Amy V Jones²,³, Ruth E Trethewey²,³ and Rachael A Evans²,³,⁴,⁵

Abstract
Approximately half of all patients with chronic obstructive pulmonary disease (COPD) attending pulmonary rehabilitation (PR) programmes are overweight or obese which negatively impacts upon dyspnoea and exercise tolerance particularly when walking. Within the obese population (without COPD), the observed heterogeneity in prognosis is in part explained by the variability in the risk of developing cardiovascular disease or diabetes (cardiometabolic risk) leading to the description of metabolic syndrome. In obesity alone, high-intensity aerobic training can support healthy weight loss and improve the constituent components of metabolic syndrome. Those with COPD, obesity and/or metabolic syndrome undergoing PR appear to do as well in traditional outcomes as their normal-weight metabolically healthy peers in terms of improvement of symptoms, health-related quality of life and exercise performance, and should therefore not be excluded. To broaden the benefit of PR, for this complex population, we should learn from the extensive literature examining the effects of exercise in obesity and metabolic syndrome discussed in this review and optimize the exercise strategy to improve these co-morbid conditions. Standard PR outcomes could be expanded to include cardiometabolic risk reduction to lower future morbidity and mortality; to this end exercise may well be the answer.

Keywords
COPD, obesity, metabolic syndrome, exercise, pulmonary rehabilitation

Prevalence of obesity in COPD
The effect of body composition upon clinical outcomes in individuals with chronic obstructive pulmonary disease (COPD) has been a focus for researchers and clinicians for decades. However, the lower end of the body mass index (BMI) spectrum and cachexia have predominated and justified by the associated poor prognosis¹ of this habitus. Towards the 21st century, the obesity epidemic encompassed patients with COPD where the prevalence of obesity (BMI > 30 m kg⁻²)² is reported to be between 10% and 30% depending on the country of origin and severity of disease.³⁻⁵ The majority of patients with COPD in typical pulmonary rehabilitation (PR)
populations and in large randomized controlled trials of pharmacological therapy are overweight. Conflicting results remain regarding the prevalence of obesity between those with and without COPD from epidemiological studies with similar, higher and lower prevalence all reported for those with COPD.

**Obesity and mortality**

In non-COPD populations, the relationship between BMI and mortality has been described by a ‘J-shaped curve’, but the magnitude of the increased risk of death per increase in BMI is unknown. Furthermore, reduced functional status, frequency and type of co-morbid conditions have a greater association with mortality than a high BMI alone. Physical inactivity is implicated as a factor in the development of obesity inferring a negative impact upon clinical outcomes. In addition, individuals with obesity, who are fit, do better than their lean unfit counterparts. Studies exploring the obesity ‘paradox’ have subcategorized individuals with obesity into metabolically healthy or unhealthy with an increase in coronary artery disease reported in those who are metabolically ‘unhealthy’ (or have the metabolic syndrome). The concept of ‘metabolically healthy’ obesity is still being debated as this group appears to sustain more cardiovascular events compared with the people of normal weight.

**BMI and prognosis in individuals with COPD**

In populations with COPD, a paradox is described whereby patients with a higher BMI live longer than those with either a low or normal index particularly in those with severe disease. The severity of COPD is predominantly assessed by the degree of airflow impairment so one explanation may be that the severity of COPD is overestimated by the physiological reduction in lung volumes in obese individuals. Furthermore, when carbon dioxide levels, muscle mass (measured by thigh cross-sectional area) and exercise capacity are included, the obesity paradox appears to disappear. Physical inactivity and co-morbid conditions both negatively impact survival in individuals with COPD, similar to the obese individuals without COPD. An increased risk of heart failure, diabetes and hypertension is seen in COPD associated with increased systemic inflammation, metabolic disturbances may be implicated as part of the pathophysiological mechanisms.

**Metabolic syndrome and COPD**

**Metabolic syndrome: an evolving definition**

The co-existence of several metabolic disturbances, namely obesity, dyslipidaemia, hypertension and hyperglycaemia, has been increasingly observed over the last century and led to the description of a ‘metabolic syndrome’. Originally defined by Reaven as ‘Syndrome X’ through identifying the relationship between insulin resistance, hyperinsulinaemia, hypertension, coronary artery disease and non-insulin-dependent diabetes mellitus. In 1998, the World Health Organization was the first to formalize the definition of a metabolic syndrome creating a working definition: “the occurrence of glucose intolerance, impaired glucose tolerance or diabetes mellitus and/or insulin resistance together with two or more of the components below”:

1. Raised arterial pressure > 160/90 mmHg
2. Raised plasma triglycerides (>1.7 mmol L⁻¹; 150 mg dL⁻¹) and/or low high-density lipoprotein-cholesterol (<0.9 mmol L⁻¹; 35 mg dL⁻¹ men; <1.0 mmol L⁻¹; 39 mg dL⁻¹ women)
3. Central obesity (males: waist to hip ratio > 0.90; females: waist to hip ratio > 0.85) and/or BMI > 30 kg m⁻²
4. Microalbuminuria (urinary albumin excretion rate > 20 μg min⁻¹ or albumin: creatinine ratio > 20 mg g⁻¹)

The term metabolic syndrome or ‘cardiometabolic syndrome’ is commonly used today to describe the interaction between cardiovascular, renal, metabolic, prothrombotic and inflammatory abnormalities leading to increased morbidity and mortality. The development of metabolic syndrome is thought to be closely associated with physical inactivity leading to the accumulation of visceral fat, which activates pro-inflammatory pathways leading to type II diabetes mellitus and cardiovascular disease.

Whilst the common features of metabolic syndrome are generally accepted, the precise definition is continuing to be refined; probably the most universally accepted is the 2009 joint consensus definition, which is slightly modified from that proposed by the International Diabetes Federation in 2006 (Table 1).
Prevalence of metabolic syndrome in COPD

Data from the 2003 to 2012 National Health and Nutrition Examination Survey collected in the United States concluded the prevalence of metabolic syndrome was 33%, with a significantly higher prevalence in women (35.6% vs. 30.3%, respectively). The prevalence of metabolic syndrome among those with COPD is reported to be anywhere between 21% and 58% depending on disease severity, geographic location, definition utilized and the assessments made. There is a suggestion that metabolic syndrome is more prevalent in those with milder airflow obstruction, but this may in part reflect the weight loss observed in the severe stages of COPD. Single studies have reported a higher prevalence of metabolic syndrome than age- and gender-matched individuals without COPD. However, pooled estimates of 10 studies reported similar (32% vs. 30%) prevalence of metabolic syndrome between COPD and healthy controls. In contrast, a prospective study, where the components of the metabolic syndrome were objectively assessed, reported a prevalence of 57% in 228 participants, which was significantly higher than healthy controls (40%). The results from this study suggested that the presence of metabolic syndrome did not impact the functional outcomes in those with COPD.

Cardiovascular disease and diabetes are significant causes of morbidity and mortality for patients with COPD, and their prevalence is significantly higher than in matched-controls. This association likely relates to several pathophysiological mechanisms, including systemic inflammation, physical inactivity and oxidative stress. International COPD guidelines recommend the proactive identification and treatment of comorbidities, yet often this is routinely performed in clinical practice. Whether earlier identification and management of metabolic syndrome in patients with COPD would lower the risk of developing cardiovascular disease and improve long-term clinical outcomes is unclear.

There is also intriguing evidence that diabetes mellitus and metabolic syndrome through an inflammatory mechanism result in airflow obstruction rather than metabolic derangement occurring in COPD as a co-morbidity. Whether effective metabolic management may slow the progression of airflow limitation in patients with COPD is yet unknown.

Obesity and metabolic syndrome are common in patients with COPD who are symptomatic and referred for PR. Despite the association between obesity in COPD and a reduced exercise performance compared to normal-weight individuals, obese individuals gain similar improvements with PR in terms of exercise capacity and health-related quality of life as patients who are normal weight. However, weight loss is not often a specific goal of PR and not achieved by most standard PR programmes.

If co-morbidities such as obesity and metabolic syndrome are to be addressed in the personalization of PR delivery, it is important to understand the current recommendations for exercise therapy for both of these conditions when COPD is not present.

Obesity and exercise interventions

Obesity is considered the result of a complex interplay of individual and environmental factors; therefore, its
management demands a comprehensive approach. Exercise is an important component of this approach, the goals of which include improvements in general health and reduction in risk of comorbid disease in addition to weight loss.33,34

Weight loss requires a shift in energy balance of which exercise forms a negative component of the equation.35 As such sufficient quantities of exercise must be achieved without compensatory behaviours such as increased calorie intake. The absolute quantity of exercise or activity appears to be more important than the type or intensity; individuals exercising at lower intensity can achieve similar weight changes by increasing duration, and greater improvements in weight reduction are seen with increasing overall amount.36,37 Results from the studies of a targeted risk reduction intervention through defined exercise (STRRIDE) study, a randomized control study investigating the effects of exercise duration and intensity in overweight and obese adults, suggest that an equivalent volume above 6–7 miles a week may be required in order to achieve weight loss. Going further, a 14-week daily exercise program where obese women were asked to expend approximately 500 kcal resulted in an average body weight reduction of 6.5%.38 A similar study in obese men where daily expenditure was approximately 700 kcal resulted in an 8% reduction over 3 months. Studies have tended to focus on aerobic exercise interventions for weight loss employing a range of modalities, including walking, stationary cycling and elliptical cross trainers, and the evidence seems to support this approach.36–38 There may be additional gains and other benefits, for example, on body composition, muscle strength and cardiovascular fitness, through the addition of high intensity or resistance exercise.36,39,40

Weight loss alone has the potential to impact several of the adverse health risk factors, which are highly prevalent in obesity, such as hypertension, dyslipidaemia and insulin resistance.41–46 However, exercise may deliver improvements in these elements above that achieved through weight reduction and even when weight remains stable.35,38,47

Where studies have specifically examined the effects of exercise in overweight and obese individuals, improvements in blood pressure, lipid profiles, glucose, glycosylated haemoglobin (HbA1c) and insulin sensitivity have been described. Again the overall volume of exercise appears to be more important than exercise modality for most of these risk factors, and modification has been demonstrated with even small increases in weekly exercise although larger volumes of moderate exercise appear to result in greater effects on lipid and glycaemic profiles.48,50–54 In those with established type II diabetes, a meta-analysis demonstrated improvements in levels of HbA1c through either aerobic, resistance or combined exercise, and such improvements have also been seen in obese groups.55,56

In addition to the effects on risk factor modification, exercise can enhance cardiovascular fitness, which is also related to a lower all-cause and cardiovascular mortality, and improve social engagement and measures of well-being.57–59

How these elements are combined to form the optimal exercise prescription to achieve both increased energy expenditure to aid healthy weight loss and evoke an important cardiovascular stimulus is still unknown. Clinicians and researchers often quote that weight supported exercise should be the initial modality. In a direct comparison of weight supported and unsupported (cycling versus treadmill walking) exercise at 60% and 80% VO2 peak, treadmill walking was associated with the greatest energy expenditure and with a higher cardiovascular stimulus in obese individuals.60 However, whether this translates to a more effective training regime with the additional factors of comfort, tolerance and compliance remains unknown.

Uncertainty exists around the translation of research to the prescription for an individual. Individual barriers, such as time, physical discomfort, and embarrassment as well as physical mobility and equipment weight limitations, are important to address.61 Adherence can be an issue, with many trials demonstrating a significant drop-out rate in the exercise intervention group.33,36,37 Therefore, individual tailoring, focusing on meaningful and realistic goals with adequate support, is a proposed strategy.33,34,36

The effects of obesity on exercise in individuals with COPD

Obesity can impair exercise capacity due to the increased mechanical load from carrying the extra weight, altered economy due to gait alterations and joint and spine discomfort. In COPD, the addition of obesity further impairs walking performance independent of the degree of airflow limitation. An interesting phenomenon has been demonstrated, whereby, in individuals with COPD and obesity, the development
of dynamic hyperinflation during cycling is lower in obese individuals compared to normal weight. Furthermore, the relationship between the progression of breathlessness with increasing ventilation is similar between walking and cycling in obese individuals with COPD, whereas in obese individuals without COPD, there is a greater progression of breathlessness with cycling compared to treadmill walking and earlier termination of exercise.

The effects of exercise training upon the metabolic syndrome

A large randomized controlled trial confirmed the evidence from smaller trials demonstrating that a period of aerobic exercise training in otherwise healthy adults with metabolic syndrome achieves a reduction in some but not all of the constituent components. Markers of insulin resistance and systemic inflammation have also been seen to be reduced after three months of high-intensity exercise training in adults with type II diabetes mellitus and the metabolic syndrome appearing to be related to gains in peak oxygen uptake (cardiorespiratory fitness) rather than weight loss. Similarly, a small study reported that high-intensity aerobic training (via an interval training regime) improved the constituent components of metabolic syndrome greater than moderate intensity training (via a continuous training regime). Other modalities of exercise training have also been tested such as resistance training where the hypothesis is based around increasing muscle mass to reduce insulin resistance. However, the results to date have been inconsistent: a meta-analysis showed resistance training significantly reduced the levels of HbA1c in adults with abnormal glucose metabolism with a reduction in body fat mass and visceral adipose tissue. The results of a large randomized trial were published a year later, concluding resistance training alone did not improve any parameters of the metabolic syndrome, whereas aerobic training alone showed a reduction in metabolic syndrome although not significantly greater than combined aerobic and resistance training. The training period was over 8 months and included adults who were overweight with dyslipidaemia. Other research has concentrated on how the effects of exercise upon metabolic syndrome may be attenuated by age, race and gender.

Overall, it appears that there is a beneficial effect of high-intensity aerobic exercise training upon the components of metabolic syndrome in adults who are overweight or obese. Correspondingly, physically active individuals have lower rates of all-cause mortality, cardiovascular disease, hypertension and importantly the metabolic syndrome. There is a convincing body of literature to support this and international guidelines promoting physical activity in all adults. Physical activity is a complex construct involving intense (aerobic exercise), mild and moderate physical activities, and time being very inactive (sedentary). Although there is interest in promoting adults (particularly those with long-term conditions) to be less sedentary, prospective data showing a reduction in long-term risk compared with increasing moderate or intense physical activity are not yet available.

Exercise training, COPD and metabolic syndrome

People with co-existing COPD and metabolic syndrome appear to benefit comparably from a course of PR as patients with COPD alone in terms of health-related quality of life and exercise performance. Similarly, studies have investigated the effects of co-morbidities on the outcomes of PR, but to date, there has been far less focus on the effects of PR on the underlying co-morbid conditions such as metabolic syndrome. A couple of studies have investigated the effects of PR in patients with COPD on cardiovascular risk by assessing systemic blood pressure, lipid levels and aortic stiffness but found differing results.

There are surprisingly few studies examining the effects of standard rehabilitation on all the constituent parts of the metabolic syndrome or on different modalities. Although high-intensity aerobic training programmes have been found to improve metabolic syndrome in those without COPD, whether the relative rather than absolute high-intensity training achieved in people with COPD would be enough to improve metabolic syndrome, or whether strategies to increase the muscle-specific stimulus would be optimal remains unanswered.

Currently, the evidence base and data for cost-effectiveness of PR is derived from patients who have significant dyspnoea rendering them unable to walk at their own pace on the flat without stopping. The aim, for this population, has been to reduce dyspnoea and improve the quality of life, which PR does very successfully. However, perhaps the focus should also be to reduce cardiometabolic risk (the risk of
developing cardiovascular disease and/or diabetes) which may be even more relevant when designing exercise or physical activity interventions for those with milder disease. The duration of standard PR is typically 6–12 weeks and it is also unknown if this is sufficient to reduce cardiometabolic risk in the longer term. Even if some benefits were observed in the short term, it is likely that long-term behaviour change and healthy lifestyle adaptations would be necessary to impact upon long-term cardiometabolic risk.

In summary, co-morbid conditions of obesity and metabolic syndrome are common in COPD. In those without COPD, exercise and high-intensity physical activity can support healthy weight loss and improve the constituent components of the metabolic syndrome. Those with COPD, obesity and/or metabolic syndrome undergoing PR appear to do as well as their normal-weight metabolically healthy peers and should therefore not be excluded. To progress the benefit of PR for this complex population, we should learn from the extensive literature examining the effects of exercise in obesity and metabolic syndrome and target the exercise strategy to ameliorate these co-morbid conditions. Standard PR outcomes should be expanded to include cardiometabolic risk reduction in order to lower future morbidity and mortality; to this end, exercise may well be the answer.

Authors' note
Rachael A Evans holds an NIHR clinical scientist fellowship CS-2016-16-020. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Ruth E Trethewey is undertaking a PhD funded by Loughborough University. Amy V Jones is undertaking a PhD funded by Loughborough University.

Author contribution
Benjamin D James, Amy V Jones and Ruth E Trethewey contributed equally to the preparation and drafting of this manuscript.

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004; 350(10): 1005–1012.
2. World Health Organization. http://www.who.int/mediacentre/factsheets/fs311/en/index.html#. World Health Organization. 30-9-2013 (Accessed 1 April 2017).
3. Vozoris NT and O’Donnell DE. Prevalence, risk factors, activity limitation and health care utilization of an obese, population-based sample with chronic obstructive pulmonary disease. *Can Respir J* 2012; 19(3): e18–e24.
4. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013; 187(7): 728–735.
5. Eriksson B, Backman H, Bossios A, et al. Only severe COPD is associated with being underweight: results from a population survey. *ERJ Open Res* 2016; 2(3): pii, 00051–2015.
6. Greening NJ, Evans RA, Williams JE, et al. Does body mass index influence the outcomes of a walking-based pulmonary rehabilitation programme in COPD? *Chron Respir Dis* 2012; 9(2): 99–106.
7. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007; 356(8): 775–789.
8. Lambert AA, Putcha N, Drummond MB, et al. Obesity is associated with increased morbidity in moderate to severe COPD. *Chest* 2017; 151(1): 68–77.
9. Vanfleteren LE, Lamprecht B, Studnicka M, et al. Body mass index and chronic airflow limitation in a worldwide population-based study. *Chron Respir Dis* 2016; 13(2): 90–101.
10. Sharma AM and Kushner RF. A proposed clinical staging system for obesity. *Int J Obes (Lond)* 2009; 33(3): 289–295.
11. Padwal RS, Pajewski NM, Allison DB, et al. Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. *CMAJ* 2011; 183(14): E1059–E1066.
12. Blair SN, Kohl HW III, Barlow CE, et al. Changes in physical fitness and all-cause mortality. A prospective study of healthy and unhealthy men. *JAMA* 1995; 273(14): 1093–1098.
13. Eckel N, Meidtner K, Kalle-Uhlmann T, et al. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. *Eur J Prev Cardiol* 2016; 23(9): 956–966.

14. Hulten EA, Bittencourt MS, Preston R, et al. Obesity, metabolic syndrome and cardiovascular prognosis: from the partners coronary computed tomography angiography registry. *Cardiovasc Diabetol* 2017; 16(1): 14.

15. Cao C, Wang R, Wang J, et al. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. *PLoS One* 2012; 7(8): e43892.

16. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2002; 166(6): 809–813.

17. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. *Thorax* 2006; 61(9): 772–778.

18. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. *Respir Med* 2013; 107(9): 1376–1384.

19. Eckel RH, Grundy SM and Zimmet PZ. The metabolic syndrome. *Lancet* 2005; 365(9468): 1415–1428.

20. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. *Annu Rev Med* 1993; 44: 121–131.

21. Castro JP, El-Atat FA, McFarlane SI, et al. Cardiometabolic syndrome: pathophysiology and treatment. *Curr Hypertens Rep* 2003; 5(5): 393–401.

22. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009; 120(16): 1640–1645.

23. Alberti KG, Zimmet P and Shaw J. Metabolic syndrome – a new world-wide definition. A consensus statement from the international diabetes federation. *Diabet Med* 2006; 23(5): 469–480.

24. Aguilar M, Bhuket T, Torres S, et al. Prevalence of the metabolic syndrome in the United States, 2003-2012. *JAMA* 2015; 313(19): 1973–1974.

25. Cebron LN, Beijers RJ, van den Borst B, et al. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. *COPD* 2016; 13(3): 399–406.

26. Watz H, Waschki B, Kirsten A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. *Chest* 2009; 136(4): 1039–1046.

27. Marquis K, Maltais F, Duguay V, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. *J Cardiopulm Rehabil* 2005; 25(4): 226–232.

28. Breyer MK, Spruit MA, Hanson CK, et al. Prevalence of metabolic syndrome in COPD patients and its consequences. *PLoS One* 2014; 9(6): e98013.

29. Fabbri LM, Luppi F, Beghe B, et al. Complex chronic comorbidities of COPD. *Eur Respir J* 2008; 31(1): 204–212.

30. GOLD guidelines 2017. Global Initiative for Chronic Obstructive Lung Disease 2017[cited 2017 Mar 15]. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/(Accessed 1 April 2017).

31. Walter RE, Beiser A, Givelber RJ, et al. Association between glycemic state and lung function: the Framingham heart study. *Am J Respir Crit Care Med* 2003; 167(6): 911–916.

32. van den BB, Gosker HR, Zeegers MP, et al. Pulmonary function in diabetes: a meta-analysis. *Chest* 2010; 138(2): 393–406.

33. Bray GA, Fruhbeck G, Ryan DH, et al. Management of obesity. *Lancet* 2016; 387(10031): 1947–1956.

34. Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. *Obes Facts* 2015; 8(6): 402–424.

35. Poirier P and Despres JP. Exercise in weight management of obesity. *Cardiol Clin* 2001; 19(3): 459–470.

36. Slentz CA, Duscha BD, Johnson JL, et al. Effects of the amount of exercise on body weight, body composition, and measures of central obesity: STRRIDE – a randomized controlled study. *Arch Intern Med* 2004; 164(1): 31–39.

37. Donnelly JE, Hill JO, Jacobsen DJ, et al. Effects of a 16-month randomized controlled exercise trial on body weight and composition in young, overweight men and women: the midwest exercise trial. *Arch Intern Med* 2003; 163(11): 1343–1350.

38. Ross R, Janssen I, Dawson J, et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. *Obes Res* 2004; 12(5): 789–798.

39. Church TS, Blair SN, Coresham S, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. *JAMA* 2010; 304(20): 2253–2262.
40. Geliebter A, Maher MM, Gerace L, et al. Effects of strength or aerobic training on body composition, resting metabolic rate, and peak oxygen consumption in obese dieting subjects. *Am J Clin Nutr* 1997; 66(3): 557–563.

41. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. *JAMA* 2003; 289(1): 76–79.

42. Hamman RF, Wing RR, Edelstein SL, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. *Diabetes Care* 2006; 29(9): 2102–2107.

43. Dattilo AM and Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr* 1992; 56(2): 320–328.

44. Jones DW, Miller ME, Wofford MR, et al. The effect of weight loss intervention on antihypertensive medication requirements in the hypertension optimal treatment (HOT) study. *Am J Hypertens* 1999; 12(12 Pt 1–2): 1175–1180.

45. Davis BR, Blaufox MD, Oberman A, et al. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. *Arch Intern Med* 1993; 153(15): 1773–1782.

46. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension* 2003; 42(5): 878–884.

47. Ades PA, Savage PD, Toth MJ, et al. High-calorie-expenditure exercise: a new approach to cardiac rehabilitation for overweight coronary patients. *Circulation* 2009; 119(20): 2671–2678.

48. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. *Ann Intern Med* 2002; 136(7): 493–503.

49. Sopko G, Leon AS, Jacobs DR Jr, et al. The effects of exercise and weight loss on plasma lipids in young obese men. *Metabolism* 1985; 34(3): 227–236.

50. Duncan JJ, Gordon NF and Scott CB. Women walking for health and fitness. How much is enough? *JAMA* 1991; 266(23): 3295–3299.

51. King AC, Haskell WL, Young DR, et al. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. *Circulation* 1995; 91(10): 2596–2604.

52. Sunami Y, Motoyama M, Kinoshita F, et al. Effects of low-intensity aerobic training on the high-density lipoprotein cholesterol concentration in healthy elderly subjects. *Metabolism* 1999; 48(8): 984–988.

53. Crouse SF, O’Brien BC, Grandjean PW, et al. Training intensity, blood lipids, and apolipoproteins in men with high cholesterol. *J Appl Physiol (1985)* 1997; 82(1): 270–277.

54. Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. *N Engl J Med* 2002; 347(19): 1483–1492.

55. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA* 2011; 305(17): 1790–1799.

56. Wing RR, Epstein LH, Paternostro-Bayles M, et al. Exercise in a behavioural weight control programme for obese patients with type 2 (non-insulin-dependent) diabetes. *Diabetologia* 1988; 31(12): 902–909.

57. Laukkanen JA, Lakka TA, Rauramaa R, et al. Cardiovascular fitness as a predictor of mortality in men. *Arch Intern Med* 2001; 161(6): 825–831.

58. Laukkanen JA, Kurl S, Salonen R, et al. The predictive value of cardiorespiratory fitness for cardiovascular events in men with various risk profiles: a prospective population-based cohort study. *Eur Heart J* 2004; 25(16): 1428–1437.

59. Penedo FJ and Dahn JR. Exercise and well-being: a review of mental and physical health benefits associated with physical activity. *Curr Opin Psychiatry* 2005; 18(2): 189–193.

60. Evans RA, Dolmage TE, Robles PG, et al. The effects of exercise modality and intensity on energy expenditure and cardiorespiratory response in adults with obesity and treated obstructive sleep apnoea. *Chron Respir Dis* 2016 April 13. pii: 1479972316643699. [Epub ahead of print].

61. Egan AM, Mahmood WA, Fenton R, et al. Barriers to exercise in obese patients with type 2 diabetes. *QJM* 2013; 106(7): 635–638.

62. Ora J, Laveneziana P, Ofir D, et al. Combined effects of obesity and chronic obstructive pulmonary disease on dyspnea and exercise tolerance. *Am J Respir Crit Care Med* 2009; 180(10): 964–971.

63. Ciavaglia CE, Guenette JA, Ora J, et al. Does exercise test modality influence dyspnoea perception in obese patients with COPD? *Eur Respir J* 2014; 43(6): 1621–1630.

64. Balducci S, Zanuso S, Nicolucci A, et al. Anti-inflammatory effect of exercise training in subjects with type 2 diabetes and the metabolic syndrome is dependent on exercise modalities and independent of weight loss. *Nutr Metab Cardiovasc Dis* 2010; 20(8): 608–617.
65. Tjonna AE, Lee SJ, Rognmo O, et al. Aerobic interval training versus continuous moderate exercise as a treatment for the metabolic syndrome: a pilot study. *Circulation* 2008; 118(4): 346–354.
66. Strasser B, Siebert U and Schobersberger W. Resistance training in the treatment of the metabolic syndrome: a systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. *Sports Med* 2010; 40(5): 397–415.
67. Bateman LA, Slentz CA, Willis LH, et al. Comparison of aerobic versus resistance exercise training effects on metabolic syndrome (from the studies of a targeted risk reduction intervention through defined exercise – STRRIDE-AT/RT). *Am J Cardiol* 2011; 108(6): 838–844.
68. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Circulation* 2007; 116(9): 1081–1093.
69. Young DR, Hivert MF, Alhassan S, et al. Sedentary behavior and cardiovascular morbidity and mortality: a science advisory from the American Heart Association. *Circulation* 2016; 134(13): e262–e279.
70. Mesquita R, Vanfleteren LE, Franssen FM, et al. Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes. *Eur Respir J* 2015; 46(2): 545–548.
71. Crisafulli E, Gorgone P, Vagaggini B, et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. *Eur Respir J* 2010; 36(5): 1042–1048.
72. Gale NS, Duckers JM, Enright S, et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? *BMC Pulm Med* 2011; 11: 20.
73. Vanfleteren LE, Spruit MA, Groenen MT, et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. *Eur Respir J* 2014; 43(5): 1306–1315.
74. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. *Am J Respir Crit Care Med* 2013; 188(8): e13–e64.
75. McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2015; (2): CD003793.